58414-52-1

Basic information

• Product Name: METHYL THIOPHENE-3-ACETATE
• Synonyms: THIOPHENE-3-ACETIC ACID METHYL ESTER;METHYL 3-THIENYLACETATE;METHYL 3-THIOPHENEACETATE;METHYL THIOPHENE-3-ACETATE;METHYL 2-(3-THIENYL)ACETATE;Methyl 3-thienylacetate~Thiophene-3-acetic acid methyl ester;Methylthiophene-3-acetate,98+%;EINECS 261-242-2
• CAS NO: 58414-52-1
• Molecular Formula: C₇H₈O₂S
• Molecular Weight: 156.2
• EINECS: 261-242-2
• Mol File: 58414-52-1.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 125 °C
• Flash Point: 125-129°C/25mm
• Appearance: /
• Density: 1.185g/cm³
• Vapor Pressure: 0.193mmHg at 25°C
• Refractive Index: 1.5215
• BRN: 4378596
• CAS DataBase Reference: METHYL THIOPHENE-3-ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL THIOPHENE-3-ACETATE(58414-52-1)
• EPA Substance Registry System: METHYL THIOPHENE-3-ACETATE(58414-52-1)

Safety Data

• Safety Statements: 23-24/25
• Hazardous Substances Data: 58414-52-1(Hazardous Substances Data)

Usage

General Description

Methyl thiophene-3-acetate is a chemical compound with the molecular formula C8H8O2S. It is a colorless to pale yellow liquid that is commonly used in the synthesis of pharmaceuticals and agrochemicals. With a strong, sweet, and floral odor, this compound is often used in the production of perfumes and fragrances. It can also be used as a flavoring agent in the food industry. Methyl thiophene-3-acetate has low toxicity and is not expected to pose a significant risk to human health or the environment when used as intended. However, proper safety precautions should still be followed when handling and using this chemical.

InChI:InChI=1/C7H8O2S/c1-9-7(8)4-6-2-3-10-5-6/h2-3,5H,4H2,1H3

Upstream product

• 67-56-1 methanol 
• 13781-65-2 2-(thiophen-3-yl)acetyl chloride 
• 6964-21-2 thiophen-3-yl-acetic acid 
• 95461-18-0 methyl 2,5-dichloro-3-thienylacetate 
• 872-31-1 3-Bromothiophene 
• 96-34-4 methyl chloroacetate 
• 79-22-1 methyl chloroformate 
• 32766-64-6 ethyl 2,5-dichloro-3-thienylglyoxylate 
• 34967-61-8 2,5-dichlorothienylacetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 124687-94-1 1-diazo-2-(thiophen-3-yl)ethanone 
• 67237-53-0 3-ethynylthiophene 

Downstream Products

• 55504-38-6 Cyclohexyl-thiophen-3-yl-acetic acid methyl ester 
• 70158-52-0 dimethyl 3-thienylmalonate 
• 16199-74-9 (+/-)-2-cyclohexyl-2-(3-thienyl)ethanoic acid 
• 73812-38-1 3-Methyl-2-thiophen-3-yl-butyramide 
• 73817-33-1 2-Cyclopentyl-2-thiophen-3-yl-acetamide 
• 51536-32-4 Cyclohexyl-thiophen-3-yl-acetyl chloride 
• 73812-48-3 2-Cyclohexyl-2-thiophen-3-yl-acetamide 
• 73812-47-2 2-Cycloheptyl-2-thiophen-3-yl-acetamide 
• 13781-67-4 3-(2-hydroxyethyl)thiophene 
• 220565-65-1 Methyl-α-(3-thienyl)-α-benzylacetate 
• 1304126-86-0 methyl 5-(2-phenyl-1-[2-(trimethylsilyl)-ethoxymethyl]-indole-6-carbonyl)thiophen-3-ylacetate 
• 1419169-74-6 2-[4-(carboxymethyl)-5-{5-[3-(carboxymethyl)-5-(2-carboxyphenyl)thiophen-2-yl]thiophen-2-yl}thiophen-2-yl]benzoic acid 
• 1419171-95-1 C₃₄H₂₈O₈S₃ 
• 1419169-78-0 5-[4-(carboxymethyl)-5-{5-[3-(carboxymethyl)-5-(3-carboxyphenyl)thiophen-2-yl]thiophen-2-yl}thiophen-2-yl]thiophene-2-carboxylic acid 

Relevant articles and documents

Synthesis and characterization of poly(3-thiophene acetic acid)/Fe 3O4 nanocomposite

Poly(3-thiophene acetic acid)/Fe3O4 nanocomposite is synthesized by the precipitation of Fe3O4 in the presence of poly(3-thiophene acetic acid) (P3TAA). Structural, surface, morphological, thermal properties and conductivity characterization/evaluation of the nanocomposite were performed by XRD, FT-IR, TEM, TGA, and conductivity measurements, respectively. The capping of P3TAA around Fe3O 4 nanoparticles was confirmed by FT-IR spectroscopy, the interaction being via bridging oxygens of the carboxylate and the nanoparticle surface through bidentate binding. The crystallite and particle size were obtained as 9 ± 2 nm and 11 ± 1 nm from XRD line profile fitting and TEM image analysis, respectively, which reveal nearly single crystalline nature of Fe 3O4 nanoparticles. Magnetization measurements reveal that P3TAA coated magnetite particles do not saturate at higher fields. There is no coercivity and remanence revealing superparamagnetic character. Magnetic particle size calculated from the theoretical fitting as 9.1 nm which coincides the values determined from TEM micrographs and XRD line profile fitting. The comparison to the TEM particle size reveals slightly modified magnetically dead nanoparticle surface.

Preparation and electrochemical performance of TEMPO-modified polyterthiophene electrode obtained by electropolymerization

A novel monomer of terthiophene with a side chain TEMPO, 4-(2,5-di(thiophen-2-yl)thiophen-3-yl)acetyl-oxy-2,2,6,6-tetramethylpiperidin-1-yloxy (TT-TEMPO) was successfully synthesized. Its corresponding polymer PTT-TEMPO was prepared via electrochemical polymerization on Pt electrode in boron trifluoride diethyl etherate solution. PTT-TEMPO film showed a uniform network structure. Compared with bare Pt electrode, PTT-TEMPO electrode exhibited high electrocatalytic performance for oxidation of benzyl alcohol in the presence of 2,6-lutidine under similar conditions. Benzyl alcohol was selectively oxidized to benzaldehyde based on in situ FTIR analysis.

Green Esterification of Carboxylic Acids Promoted by tert-Butyl Nitrite

In this work, the green esterification of carboxylic acids promoted by tert-butyl nitrite has been well developed. This transformation is compatible with a broad range of substrates and exhibits excellent functional group tolerance. Various drugs and substituted amino acids are applicable to this reaction under near neutral conditions, with good to excellent yields.

AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS

Provided herein are amino-benzoisothiazole and benzoisothiadiazole amide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, retinal diseases such as acute macular degeneration (AMD) and diabetic macular edema (DME), diseases and conditions characterized by inflammatory processes, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. Also provided are compositions (e.g., pharmaceutical compositions) comprising the compounds provided herein.